Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of IBI3016 in Japanese Participants With Mild to Moderate Hypertension
jRCT2051260146Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Jul 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3016 in essential hypertension (5 arms), sponsored by Innovent Biologics. Primary endpoints: Safety endpoints, Tolerability and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
IBI3016
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2051260146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260146.